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doi:10.1016/j.pedneo.2010.12.011Background: Inhaled b2-adrenergic receptor (b2-AR) agonists are the mainstay of treatment of
acute asthma. Polymorphisms of the b2-AR, especially codons 16, 27, and 164, may affect the
functions of the receptor. This study was conducted to investigate whether different poly-
morphisms of the b2-AR are related to the treatment responses of an inhaled b2-AR agonist
in children with nocturnal and nonnocturnal asthma in Taiwan.
Methods: The nocturnal asthma group consisted of 27 children (mean age of 10.3 2.4 years),
and the nonnocturnal asthma group consisted of 24 patients (mean age of 9.9 3.0 years).
Allele-specific polymerase chain reaction was performed to determine 16, 27, and 164 loci
alleles of b2-AR genetic polymorphisms, and peak expiratory flow (PEF) was measured before
and 1 hour after inhalation of 0.2 mg/kg/dose of terbutaline to determine the treatment
response in these patients.
Results: The polymorphisms of b2-AR 27 but not 16 or 164 were significantly associated with
the response to terbutaline nebulizer (p< 0.05). The polymorphism of b2-AR 16 was associated
with nocturnal asthma (pZ 0.027). The Gly16 allele was more prevalent in the nocturnal
asthma group (9/27; 33.3%) than in the nonnocturnal asthma group (3/24; 12.5%). Arg16 allele
was less prevalent in the nocturnal asthma (3/27; 11.1%) than in the nonnocturnal asthma
group (10/24; 41.7%). There was also a linkage disequilibrium found between b2-AR 16 (Arg/
Arg) and b2-AR 27 (Gln/Gln).t of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Neihu, Taipei 114,
ahoo.com.tw (H.-C. Fan).
an Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
Polymorphisms of the b2-AR and nocturnal asthma 19Conclusion: These findings suggest that polymorphisms of b2-AR 16 are related to nocturnal
asthma and polymorphisms of b2-AR 27 are associated with the variable responses to the
inhaled terbutaline in children with nocturnal and nonnocturnal asthma.
Copyright ª 2011, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
The caliber of the human airway is not a constant. It may
increase during the day and decrease at night.1 Evidence
shows that this circadian fluctuation in the caliber of both
upper and lower airways is amplified in disease states, such
as asthma.1 This is one of reasons why most in-hospital
sudden deaths and episodes of ventilator arrest from
asthma occur at night. Nocturnal asthma, a unique subset
of patients with asthma, is of particular interest because
patients with this disease show that their caliber of the
airways decreases and causes peak dyspnea and wheezing
between 2 and 6 AM.2 Moreover, the disturbance of sleep
because of nocturnal asthma may impair performance
during the day. Therefore, it will be helpful if patients with
nocturnal asthma can be early identified and receive proper
treatment.
Although inhaled b2-adrenergic agonists are the main-
stay of treatment of acute asthma, it is still not clear why
patients with asthma show various responses to the same
inhaled b2 agonists. After the b2-adrenergic receptor (b2-
AR) gene was cloned in 1987,3 the role of the b2-AR gene
in determining disease response and disease severity is
now reasonably well accepted.4 The gene encoding this
G-protein-coupled b2-AR is located on the chromosome
5q31-33 and is highly polymorphic. To date, nine distinct
polymorphisms in the b2-AR gene have been reported.
5
Each of these polymorphisms represents a single base pair
substitution. Four of these polymorphisms result in amino
acid substitutions at amino acids 16, 27, 34, and 164,
whereas the other five are silent mutations located at
amino acids 84, 175, 351, 366, and 413.6 A question here is
whether these polymorphisms might explain altered phar-
macologic responses to b2-AR agonist treatment. Indeed,
studies have suggested that these polymorphisms may be
associated with asthma of different severity.7,8 Three of
these polymorphisms have been found to alter the receptor
function by site-directed mutagenesis and recombinant
expression studies,8e10 including substitutions of glycine for
arginine at amino acid position 16 (Arg16/Gly16), gluta-
mic acid for glutamine at position 27 (Gln27/Glu27), and
isoleucine for threonine at position 164 (Thr164/ Ile164).
Some studies suggest that the Gly16 allele showed
enhanced downregulation of b2-AR, whereas the Glu27
allele was relatively resistant to downregulation of b2-AR
during exposure to b2-AR agonists.
8,9 The Ile164 variant
markedly altered ligand binding and coupling proper-
ties.9,10 All these in vitro findings are consistent with the
concept that a defective b2-AR may be a primary causal
abnormality in asthma.
Using asthmatic children, we want to know the differ-
ence between b2-AR polymorphisms at amino acid positions
16, 27, and 164 in Taiwanese children with nocturnal andnonnocturnal asthma. Moreover, to investigate the
responses of patients with nocturnal and nonnocturnal
asthma in the treatment with an inhaled adrenergic
agonist, we used terbutaline, a selective b2-AR stimulator,
which increases the diameter of the airway via relaxation
of bronchial smooth muscle within few minutes.11 The
polymorphisms and changes of the peak expiratory flow
rate (PEFR) before and after inhaled terbutaline treatment
were correlated with when the children required the use of
bronchodilator in acute asthma.
2. Materials and Methods
2.1. Study participants
Children with a diagnosis of asthma for at least 1 year
attending our emergency department were enrolled for
the study. Asthma was defined using the criteria of the
American Thoracic Society.12 Exclusion criteria included
use of oral or inhaled steroids, cromolyn, antibiotics, or any
investigational drug within 2 weeks, moderate to severe
asthma exacerbations or upper respiratory tract infection
within 2 weeks, and presence of other lung or cardiac
diseases as the cause of patient symptoms before this
study. Home peak expiratory flow monitoring was per-
formed. PEFRs were measured by using a peak flow meter
(Mini-Wright; Armstrong Industries, Northbrook, IL, USA).
Patients were separated into those with nocturnal asthma
or those with nonnocturnal asthma. Nocturnal asthma was
defined as a documented fall in PEFR of >20% on at least
four of seven nights of testing at home13 or on the history of
early morning awakening, dyspnea, wheezing, and cough
occurs between 2 and 6 AM on 3 consecutive days. The
patients with nonnocturnal asthma were those with asthma
attacks beyond the range of 2e6 AM. Informed consent was
obtained from the parents in each case. Peak flow meter
was performed before and 1 hour after inhalation of
0.2 mg/kg/dose of terbutaline (Brincanyl; Astra-Zeneca,
London, UK) in a 3-mL isotonic sodium chloride solution
administered with a handheld disposable updraft nebulizer
(whisper Jet nebulizer; Intec, Marquest Medical products,
Englewood, CO, USA).14 PEFR0 was the PEFR before the
treatment with terbutaline nebulizer when the patients
were sent to our pediatric emergency room for asthma
attack. PEFR1 was defined as the PEFR 1 hour after inha-
lation of terbutaline. ΔPEFR was the percentage change of
PEFR0 to PEFR1.
2.2. Genotyping of b2-AR polymorphism
Genomic DNA from peripheral whole blood was prepared
by standard phenol/chloroform extraction procedures.15
20 M.-Y. Lee et alPolymorphisms of the b2-AR coding block were delineated
using an allele-specific polymerase chain reaction (PCR)
approach.8 Allele-specific PCR was performed to assess
polymorphisms at nucleic acids 46, 79, and 491, which
result in changes in the encoded amino acids at positions
16, 27, and 164 of the receptor protein. The genotypes are
abbreviated as Arg16, Gly16, Gln27, Glu27, Thr164, and
Ile164. Genomic DNA was isolated from 2 mL of peripheral
blood. PCRs were carried out in a volume of 50 mL using
100 ng of genomic DNA. To delineate the two poly-
morphisms at nucleic acid 46, the primer pairs used were
50-CTTCTTGCTGGCACCCAATA-30 (sense) and 50-CCAATT
TAGGAGGATGTAAACTTC-30 (antisense) or the same anti-
sense primer and 50-CTTCTTGCTGGCACCCAATC-30 (sense).
The generated PCR product size using these primers was
913 base pairs (bp). The primer pair for delineating the two
polymorphisms at nucleic acid 79 was 50-GGACCACGACGT
CACGCAGC-30 (sense) and 50-ACAATCCACACCATCAAGAAT-30
(antisense) or the same antisense primer and 50-GGAC
CACGACGTCACGCAGG-3 (sense). Use of these primers
resulted in a product with a molecular size of 442 bp. For
the detection of polymorphisms at nucleic acid 491, the
primer pair used was 50-TGGATTGTGTCAGGCCTTAT-30
(sense) and 50-CACAGCAGTTTATTTTCTTT-30 (antisense) or
the same antisense primer and 50-TGGATTGTGTCAGGCCT
TAC-30 (sense). The PCR product size from these primers
was 662 bp. In general, a 0.1 mg (2 mL) of DNA template was
added to 50 mL of reaction mixtures containing 0.5 mL of
Takara Taq DNA polymerase (Takara Shuzo Co.; Kyoto,
Japan), 1 mL of each primer, 1 mL of dinucleoside 50-
triphosphate, 5 mL of 10 PCR reaction buffer, and 39.5 mL
of deionized water. The reaction consisted of an initial
denaturation at 94C for 5 minutes; followed by denatur-
ation at 94C for 2 minutes, 55C for 1 minute, and 72C for
1 minute for 35 cycles; and a final extension of 10 minutes
at 72C (DNA Thermal Cycler; Perkin-Elmer Co., Norwalk,
CT, USA). The results of electrophoresis of the PCR products
could effectively differentiate the polymorphisms in these
three alleles. The allele-specific PCR technique was verified
by direct dideoxy sequencing (PE Applied Biosystems,
Foster City, CA, USA) of PCR products that were generated
using sequencing primers that were different from those
used in the PCR.
2.3. Statistical analysis
Demographic data, including age, sex, and initial PEFR, were
recorded and analyzed. The patients’ ages and pulmonary
function test data were expressed as mean standard devi-
ation. The association of the b2-AR polymorphisms genotype
betweennocturnal asthmaandnonnocturnal asthmapatients
was examined by the c2 and one-way analysis of varianceTable 1 Demographic data of nocturnal and nonnocturnal asth
Classification of asthma Sex (M/F) Age (yr)
Nonnocturnal asthma 8/16 10.3 2.4
Nocturnal asthma 8/19 9.9 3.0
Values given as mean standard deviation.
M/FZmale/female; PEFRZ peak expiratory flow rate; b2-ARZ b2-atests (SPSS 16.0, SPSS Inc., Chicago, IL, USA). The p values
<0.05 were considered statistically significant.
3. Results
3.1. Demographic data
There were a total of 51 participants in our study, 16 male
and 35 female. Mean age of the participants was 10.1 2.6
years. The nocturnal asthma group consisted of 27 patients
(mean age of 10.3 2.4 years; 8 male and 19 female), and
the nonnocturnal asthma group consisted of 24 patients
(mean age of 9.9 3.0 years; 8 male and 16 female). No
patients regularly used inhaled bronchodilator. Mean PEFR0,
PEFR1, and ΔPEFR in the nocturnal asthma group were
204.8 42.5%, 232.2 46.2%, 14.0 10.9%, respectively,
whereas those in nonnocturnal asthma group were
185.6 51.9%, 222.5 58.6%, 9.6 11.9%, respectively
(Table 1). There were no significant differences in the
demographic data and initial PEFR between the nocturnal
and the nonnocturnal asthma groups.
3.2. Response to treatment with terbutaline
nebulizer according to the polymorphisms of b2-AR
The allele frequencies found in this study population were
0.49 for Gly16, 0.51 for Arg16, 0.41 for Gln27, 0.59 for
Glu27, 0.5 for Thr164, and 0.5 for Ile164. When b2-AR
polymorphisms at amino acid positions 16, 27, and 164 were
correlated with mean ΔPEFR, the polymorphisms of b2-AR 27
were significantly associated with mean ΔPEFR (homozygous
Gln/Gln vs. heterozygous Gln/Glu, pZ 0.012; homozygous
Gln/Gln vs. homozygous Glu/Glu, pZ 0.001). There was
no correlation found between the polymorphisms of b2-AR 16
or 164 and the ΔPEFR after terbutaline treatment (Table 2).
3.3. Correlation of genotypes with nocturnal and
nonnocturnal asthma
The distribution of Arg-Gly16, Gln-Glu27, and Thr-Ile164
of b2-AR polymorphisms with nocturnal asthma or non-
nocturnal asthma patients is shown in Table 3. The poly-
morphisms at position 27 (Gln or Glu) and position 164 (Thr
or Ile) were not different between both groups. A linkage
disequilibrium was found in participants carrying Arg16,
who also carried Gln27 (84.6%) (Table 4).
4. Discussion
Asthma is a polygenic disease, but so far no clear genotype-
phenotype relationships have emerged. Although evidencema groups
PEFR0 (L/min) PEFR1 (L/min) D PEFR (%)
204.8 42.5 232.2 46.2 14.0 10.9
185.6 51.9 222.5 58.6 9.6 11.9
drenergic receptor.
Table 2 Response to treatment with terbutaline nebulizer according to polymorphisms of b2-AR
Genotype ΔPEFR (%) p
b2-AR 16 Homozygous Arg/Arg 12.2 12.1
Heterozygous Arg/Gly 13.1 9.4 NS
Homozygous Gly/Gly 8.0 14.9
b2-AR 27 Homozygous Gln/Gln 8.2 9.4
Heterozygous Gln/Glu 10.7 9.0 <0.05
Homozygous Glu/Glu 23.4 14.4
b2-AR 164 Homozygous Thr/Thr 3.8 11.6
Heterozygous Thr/Ile 12.3 11.3 NS
Homozygous Ile/Ile 12.1 14.2
ΔPEFR is the percentage change of PEFR before and after 1 hour treatment with terbutaline nebulizer.
Values given as mean standard deviation.
NSZ not significant; PEFRZ peak expiratory flow rate.
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critical determinant of functions of this receptor in vitro,10
there are still inconsistencies between in vitro findings and
asthma phenotypes. Therefore, it is of interest to investi-
gate the associations between polymorphisms of b2-AR and
nocturnal asthma and clarify whether the variant b2-AR
receptors may affect asthmatic patients’ response to
inhaled b2-AR agonists. Because the analysis of poly-
morphisms of b2-AR from peripheral leukocyte can be
surrogate for b2-AR expressed on bronchial smooth muscle
and other cell types relevant to asthma,15 DNA of periph-
eral blood from 51 asthmatic children was analyzed by
using an allele-specific PCR approach.8 Our results show
that the allele frequencies found in this study were 0.49 for
Gly16, which was compatible with the data of Asian chil-
dren with asthma (0.4 for Gly16).16 The allele frequencies
were 0.51 for Arg16, 0.41 for Gln27, 0.59 for Glu27, 0.5 for
Thr164, and 0.5 for Ile164. The difference between our
data and those of other studies6,8,16,17 may be because of
variability in allele frequencies of b2-AR in different ethnic
populations, which has yet to be elucidated.
Airway hyperresponsiveness to a variety of stimuli is
one of the essential components of the manifestations ofTable 3 Association between the frequency of genotypes of th
Genotypes Frequenc
Nocturna
% (nZ 27
b2-AR 16 Homozygous Arg/Arg 11.1
Heterozygous Arg/Gly 55.6
Homozygous Gly/Gly 33.3
b2-AR 27 Homozygous Gln/Gln 48.1
Heterozygous Gln/Glu 40.8
Homozygous Glu/Glu 11.1
b2-AR 164 Homozygous Thr/Thr 11.1
Heterozygous Thr/Ile 81.5
Homozygous Ile/Ile 7.4
Values given as percentages.
b2-ARZ b2-adrenergic receptor; NS = not significant.asthma. Interestingly, individuals with Gln27 may have
augmented airway hyperresponsiveness to endogenous
catecholamines, resulting in increased airway sensitivity to
proinflammatory stimuli and leading to some extent of
long-term airway inflammation.7 Children in Argentina with
homozygous Gln27 developed significantly greater bron-
chodilator desensitization to b2-AR agonist than those with
homozygous Glu27.18 In addition, Gln27 has been also
reported to be associated with an elevated immunoglobulin
E level6 and may be more susceptible to inflammation and
bronchoconstriction. Another study shows that the poly-
morphism of b2-AR 27 has a linkage disequilibrium in a locus
related to the control of immunoglobulin E levels nearby on
chromosome 5q,19 which contains a number of cytokine
genes important in the generation of Type 2 T helper cell
responses, including those for interleukin (IL)-4, IL-5, IL-9,
and IL-13.20 In contrast, Glu27 has been reported to be
related to a lower degree of airway reactivity.21 Site-
directed mutagenesis experiments have shown that
although agonist binding and coupling to adenylyl cyclase is
intact in the Glu27 b2-AR polymorphism, it was associated
with impaired agonist downregulation.6,10 In our study, the
polymorphism of b2-AR 27, although not related to individualse b2-AR polymorphism and asthma groups
y p
l asthma,
)
Nonnocturnal asthma,
% (nZ 24)
41.7
45.8 0.027
12.5
54.2
10.8 NS
25
4.2
87.5 NS
8.3
Table 4 Association between genotypes of the polymorphisms of b2-AR 16 and 27
Polymorphism 16 Polymorphism 27
Gln/Gln Gln/Glu Glu/Glu Total
Arg/Arg 11 (84.6%) 0 (0%) 2 (15.4%) 13
Arg/Gly 8 (30.8%) 13 (50.0%) 5 (19.2%) 26
Gly/Gly 7 (58.3%) 3 (25.0%) 2 (16.7%) 12
Values given as number (%).
b2-ARZ b2-adrenergic receptor.
22 M.-Y. Lee et alwith or without nocturnal asthma, showed a significant
association with the mean ΔPEFR (Table 3). Individuals with
homozygous Glu27 had a higher increase of ΔPEFR than
those with homozygous Gln27. Therefore, patients with
b2-AR Glu27 may have a more augmented response to ter-
butaline inhalation than those with b2-AR Gln27 in this
study. We suggest that Glu27 may play a role in assisting b2-
AR to respond to an inhaled terbutaline in patients with
asthma.
Recent clinical reports provide evidence that b2-AR
polymorphisms at position 16 have an important role. A
cross-sectional survey revealed that possessing with
homozygous Arg16 may predispose children and young
adults to asthma exacerbation.22 Another group found that
PEFR was reduced in patients with homozygous Arg16.23,24
A Chinese group reported that they detected 72% homozy-
gous Gly16 in patients with nocturnal asthma.25 In addition,
a case report also supports the concept that homozygous
Arg16 was connected to asthma in one patient with asthma
in an uncontrolled situation.26 However, Turki et al8
reported that Gly16 allele appeared more frequently
among pediatric patients with nocturnal asthma than
among patients with nonnocturnal asthma, and Gly16 of b2-
AR was significantly associated with nocturnal falls in PEFR
in individuals with asthma. Reihsaus et al5 concluded that
the Gly16 was associated with the more severe form of
asthma, and patients with Gly polymorphism may correlate
with a lack of benefit from b2-AR agonist therapies, thereby
necessitating the use of corticosteroids and/or immuno-
therapy. Cell study shows that Gly16 is associated with
increased agonist-promoted downregulation of the b2-AR
compared with Arg16.9,10 These results imply that when
compared with patients without this genotype, asthmatic
individuals with homozygous Gly16 may be more likely to
show less improvement after treatment with short acting
b2-AR agonist, even leading to respiratory failure and death
after inhalation of bronchodilators. This enhanced agonist-
mediated b2AR downregulation may also contribute to the
pathogenesis of nocturnal asthma, especially in patients
with Gly16 polymorphism.6 Our data show that the Gly16
allele was more prevalent in the individuals with nocturnal
asthma than in those with nonnocturnal asthma. Further-
more, a strong linkage disequilibrium between the two
polymorphisms in patients, with the Arg16 allele having
84.6% of individuals carrying the Gln27 allele. In fact, as in
previous reports, above 90% of all chromosomes carrying
Arg16 also carried Gln27.23,27 We think that the amino acid
substitution at codons 16 and 27 of the b2-AR sequence may
result in conformational changes, which may possibly affect
the function of b2-AR and the incidence of nocturnalasthma, and that more studies, such as knock-in variant
codons of b2-AR in vivo may answer these questions.
Amino acid 164 is the third most frequent b2-AR poly-
morphism. This location may be important because it is
within the fourth transmembrane domain and adjacent to
serine 165, which has been proposed to interact with the b-
carbon hydroxyl group of adrenergic ligand.28 Site-directed
mutagenesis studies show that the Ile164 protein displays
significant dysfunction, with a 50% decrease in maximal
stimulation of adenylyl cyclase compared with the wild-
type receptor. In addition, the Ile164 form displayed
decreased affinities for b-agonists. Therefore, it has been
suggested that the Ile164 form may be associated with
diminished responsiveness to b-agonists.28 Our data show
that there was no statistically significant association
between 164 b2-AR polymorphisms and nocturnal asthma
and the change of PEFR. We think that 164 b2-AR poly-
morphisms may play a minor role in the nocturnal asthma in
our study.
In conclusion, the distribution of b2-AR polymorphisms is
variable among different ethnic groups. Based on our
findings, these polymorphisms may be related to the
phenotypic modulation of nocturnal asthma and in the
determination of the treatment responses of b2-AR
agonists. We suggest that the specific polymorphisms of b2-
AR may distribute in the particular phenotype of asthma in
Taiwanese children. The different genotypes of b2-AR may
affect the responses to extrinsic or intrinsic b2-AR agonists.
A large-scale prospective study assessing the effects of b2-
AR haplotypes on the response to chronic use of short- and
long-acting b2-AR agonists is required in the design of
clinical trials involving a new generation b2-AR agonists.Acknowledgments
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